-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: ELISA Platform Enables Precision Life Science Research
Author:
InnoModels Biotechnology
Release time:
2024-02-02
InnoModels Biotechnology has once again launched the ELISA (Enzyme-linked Immunosorbent Assay) platform, an important tool for leading scientific innovation, providing researchers with an efficient, accurate and sensitive tool for life science research.The excellent performance of the ELISA platform will vigorously promote the progress of the biomedical field, and provide reliable support for the diagnosis and treatment of diseases and the development of new drugs.
Technical features of ELISA platform
1. High sensitivity and precision:
The ELISA platform utilizes advanced optical detection technology and high quality antibodies to ensure highly sensitive detection of trace biomolecules. Its accuracy enables researchers to accurately determine the content of target molecules in biological samples, providing a reliable data base for life science research.
2. Diverse detection targets:
The ELISA platform is widely applicable to the detection of a wide range of biomolecules, including proteins, antibodies, hormones and so on. Researchers can choose the appropriate ELISA kits according to their research needs, realizing rapid and accurate detection of different biomarkers and providing support for a wide range of research fields.
3. Flexibility and scalability:
ELISA platform has flexible operation flow and scalable detection range, which is suitable for small-scale research experiments to large-scale high-throughput screening. This flexibility makes the ELISA platform ideal for a wide range of research needs and provides researchers with greater freedom in experimental design.
4. Automation and high throughput:
The ELISA platform combines advanced automation technology to enable high-throughput biomolecule detection. Automation greatly improves the efficiency of experiments and reduces human errors, allowing researchers to focus on the interpretation of results and data analysis.

5. User-friendly data analysis software:
The platform is equipped with user-friendly data analysis software that enables researchers to easily access, interpret and share experimental data. This feature further lowers the threshold of use and enables more researchers to fully utilize the ELISA platform for efficient experimental design and data interpretation.
Research Applications and Future Prospects
1. Disease marker research:
ELISA platform has important application value in disease marker research, which can help researchers screen potential biomarkers quickly and accurately, and provide powerful support for early diagnosis and treatment of diseases.
2. Drug development and pharmacodynamics research:
In drug development and pharmacodynamics research, ELISA platform can be used to evaluate the effects of drugs on biomolecules, providing reliable data support for new drug development.
3. Basic biological research:
ELISA platforms are not only suitable for clinical applications, but also have a wide range of applications in basic biological research, providing an important tool for researchers to gain a deeper understanding of the expression and function of biomolecules.
Conclusion
With its excellent technical features, the ELISA platform from InnoModels Biotechnology will become an indispensable tool in the field of life science research. With its wide application in various fields, the ELISA platform is expected to further promote the development of scientific research and contribute more to human health and medical progress.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd